23:11 , Jul 12, 2019 |  BC Extra  |  Company News

July 12 management tracks: Linus Lin joins Lilly’s Chorus; plus Ocular, Aptinyx

Eli Lilly and Co. (NYSE:LLY) named Linus Lin managing director of its Chorus R&D unit. He was previously VP and head of Lilly China Innovation and Partnerships. Eye disease company Ocular Therapeutix Inc. (NASDAQ:OCUL) hired...
00:20 , Jun 11, 2019 |  BC Extra  |  Clinical News

June 10 Clinical Quick Takes: Oral semaglutide superior to Jardiance, non-inferior to Victoza; plus Aptinyx and Eli Lilly

Novo’s oral semaglutide meets in Phase III trials  Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) reported results from two Phase III trials of its oral semaglutide in Type II diabetes. In PIONEER 2, oral semaglutide, a...
00:04 , Apr 6, 2019 |  BioCentury  |  Finance

Everybody up

Biotech stocks were off to a strong start in 1Q19, with 71% of companies tracked by BioCentury seeing market cap growth in the quarter. Across all market cap bands, biotechs saw a median gain of...
18:43 , Jan 18, 2019 |  BC Week In Review  |  Clinical News

Aptinyx's pain compound misses Phase II endpoint

Aptinyx Inc. (NASDAQ:APTX) said all three doses of NYX-2925 missed the primary endpoint in a Phase II trial to treat pain associated with diabetic peripheral neuropathy. The primary endpoint measured mean change in average daily...
18:36 , Jan 16, 2019 |  BC Extra  |  Clinical News

Aptinyx tumbles after pain compound misses Phase II endpoint

Aptinyx Inc. (NASDAQ:APTX) lost $11.85 (66%) to $5.98 Wednesday after it said all three doses of NYX-2925 missed the primary endpoint in a Phase II trial to treat pain associated with diabetic peripheral neuropathy. The...
21:46 , Nov 16, 2018 |  BioCentury  |  Finance

SVB Leerink’s full suite

The planned $280 million acquisition of Leerink Partners by SVB Financial Group (NASDAQ:SIVB) is expected to provide biotechs with a new one stop shop for financial services. SVB, a commercial lender with a dedicated healthcare...
23:21 , Jul 13, 2018 |  BioCentury  |  Finance

Pause for politics

The near record-setting pace of 1H18 capital markets activity isn’t likely to be replicated this half, but that won’t be because of changes to sector fundamentals. Instead, it’s likely the consequence of macroeconomic and geopolitical...
19:15 , Jun 22, 2018 |  BC Week In Review  |  Financial News

IPO roundup: Avrobio, Aptinyx, Magenta, Kezar, Xeris

Five biopharmas priced IPOs late on June 20, raising a total of more than $460 million. Four of the five upsized their offerings to sell more shares than anticipated; one of those, Avrobio, also priced...
04:46 , Jun 21, 2018 |  BC Extra  |  Financial News

Four companies in IPO quintet post first-day gains

Four of the five biopharmas that priced IPOs late Wednesday posted gains on Thursday. Cell therapy company Avrobio Inc. (NASDAQ:AVRO) had the biggest first-day bump, climbing $12.20 (64%) to $31.20, while three others posted double-digit...
18:33 , May 25, 2018 |  BC Week In Review  |  Financial News

Aptinyx proposes $80M IPO

Neurology company Aptinyx Inc. (Evanston, Ill.) proposed to raise $80 million on May 23 in an IPO on NASDAQ underwritten by J.P. Morgan, Cowen, Leerink and BMO Capital Markets. The company expects data in 1H19...